Neratinib (Figure 1) is an irreversible EGFR, HER2/4 receptor tyrosine kinase inhibitor that was approved for use in the treatment of HER2-positive breast cancer on 17 July 2017 [10]. Here, EGFR is linked to breast carcinoma.